Stay updated on Surufatinib and Tislelizumab Combination in Solid Tumors Clinical Trial
Sign up to get notified when there's something new on the Surufatinib and Tislelizumab Combination in Solid Tumors Clinical Trial page.

Latest updates to the Surufatinib and Tislelizumab Combination in Solid Tumors Clinical Trial page
- Check2 days agoChange DetectedThe page's revision label was updated from v3.5.4 to v3.5.5, indicating a new release of the study record or page content.SummaryDifference0.0%

- Check9 days agoNo Change Detected
- Check16 days agoNo Change Detected
- Check24 days agoChange DetectedThe page now displays Revision: v3.5.4, replacing Revision: v3.5.3. This indicates a newer version of the study record.SummaryDifference0.0%

- Check45 days agoChange DetectedThe page’s displayed release/version marker was updated from “Revision: v3.5.2” to “Revision: v3.5.3” without changing the study information shown.SummaryDifference0.0%

- Check53 days agoChange DetectedRevision updated: v3.5.2 added; v3.5.0 removed.SummaryDifference0.0%

- Check74 days agoChange DetectedAdded thyroid gland undifferentiated (anaplastic) carcinoma and small cell lung carcinoma to the study's listed conditions.SummaryDifference0.1%

- Check81 days agoChange Detected- Revision: v3.5.0 updated from v3.4.3.SummaryDifference0.0%

Stay in the know with updates to Surufatinib and Tislelizumab Combination in Solid Tumors Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Surufatinib and Tislelizumab Combination in Solid Tumors Clinical Trial page.